ABCB1: is there a role in the drug treatment of Parkinson’s disease?

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17425255.2018.1416096PMID 29224383
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease

  2017cited by this paper
• Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in wistar rats

  2016cited by this paper
• Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease

  2013cited by this paper
• Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

  2013cited by this paper
• A Double-Blind, Delayed-Start Trial of Rasagiline In Parkinson's Disease

  2010cited by this paper
• ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders

  2010cited by this paper
• Occupation and risk of parkinsonism: a multicenter case-control study.

  2009cited by this paper
• A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

  2009cited by this paper
• ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs

  2009cited by this paper
• nteractions between antiparkinsonian drugs and ABCB 1 / P-glycoprotein t the blood – brain barrier in a rat brain endothelial cell model

  2008cited by this paper
• Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA

  2008cited by this paper
• Drugs as P-glycoprotein substrates, inhibitors, and inducers

  2002cited by this paper
• Integrity of the blood-cerebrospinal fluid barrier in early Parkinson's disease.

  2001cited by this paper
• SELEDO: a 5‐y‐ear long‐term trial on the effect of selegiline in early parkinsonian patients treated with levodopa

  1999cited by this paper
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa

  1996cited by this paper
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.

  1996cited by this paper
• Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients

  1995cited by this paper
• Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

  1995cited by this paper

• Unraveling novel mechanisms of ATP-Binding cassette (ABC) transporter in insulin Resistance-induced amyloidogenesis

  2025cites this paper
• Gatekeeper of the brain: unraveling the role of ABCB1 in Parkinson’s disease progression and therapy

  2025cites this paper
• Fiscalin Derivatives as Potential Neuroprotective Agents

  2022cites this paper
• Systematic analysis of the molecular mechanisms mediated by coffee in Parkinson’s disease based on network pharmacology approach

  2021cites this paper
• Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice

  2020cites this paper
• Alteration in the Function and Expression of SLC and ABC Transporters in the Neurovascular Unit in Alzheimer’s Disease and the Clinical Significance

  2020cites this paper
• Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.

  2019cites this paper
• ABC transporters in neurological disorders: an important gateway for botanical compounds mediated neuro-therapeutics.

  2019cites this paper
• Leaky brain in neurological and psychiatric disorders: Drivers and consequences

  2018cites this paper